Composition capable of relieving chronic skin itching, preparation method and application

Abstract

The invention provides a composition for relieving chronic skin itching, a preparation method and application, and belongs to the field of daily chemicals. The composition capable of relieving chronic skin itching comprises a water phase, a non-water phase and an emulsifier. The water phase comprises a water-soluble medicinal and edible substance and an active substance phase A, the non-water phase comprises a non-water-soluble medicinal and edible substance and an active substance phase B, and the emulsifier comprises alcohol-soluble protein. The composition comprises multifunctional effective active components with functions of moisturizing, repairing, anti-inflammation and the like, the effective components are coated by the prolamin to form a stable emulsion, and the composition is suitable for various washing and skin care product formulas and can effectively relieve chronic skin itch.

Description

Technical Field

[0001] The invention relates to the field of daily chemicals, and in particular to a composition for relieving chronic skin itching, a preparation method and an application thereof. Background Art

[0002] Itch is a common symptom of many skin diseases. Its pathogenesis is not yet fully understood and involves a complex network system of skin cells, immune cells and nerve cells.

[0004] According to the different itch-causing mechanisms, itch mediators can be divided into two categories: histamine-dependent itch signaling pathways that induce itch and histamine-independent itch signaling pathways that cause itch.

[0005] In daily life, some people experience dry skin, reduced sebum secretion, micro-inflammation, and disordered skin flora, which makes skin itching more common. The skin has four layers of barriers: microbial barrier, chemical barrier, lipid barrier, and immune barrier. They are interconnected, forming a complete barrier system and a powerful defense system. Skin aging leads to dry skin and increased pH value, and the barrier function declines, reducing the ability to protect the skin. The skin is susceptible to external stimuli, which leads to the susceptibility of pruritus.

[0006] Usually, based on the clinical manifestations, it is called: chronic idiopathic pruritus, and its clinical characteristics are: ① It is more common in the elderly; ② Itching occurs in multiple parts; ③ Itching is often moderate or severe; ④ It may not be accompanied by skin lesions, or it may manifest as secondary skin lesions such as scratches; ⑤ Nighttime sleep is often affected.

[0007] Common treatment methods mainly include hormone drug therapy, but the effects of treatment methods vary. Itching symptoms are prone to recurrence after stopping treatment, and long-term use of glucocorticoids has adverse effects on the skin barrier and glucocorticoid absorption on the whole body. Immunosuppressants can be used for some itching, but during use, attention should be paid to monitoring liver and kidney function, and preventing adverse reactions such as hypertension, bone marrow suppression, and infection. Chronic itching is common in elderly patients, who often have multiple underlying diseases, making the cause of itching complex and difficult to identify. When using medications, special attention should be paid to drug interactions and adverse drug reactions caused by poor tolerance. Therefore, medication is difficult in most cases.

[0008] Daily chemicals are indispensable in people's lives and are used frequently. If daily chemical products are used to relieve chronic skin itching instead of some drugs, it may effectively relieve the trouble of chronic skin itching for some people. However, in the face of complex causes of chronic skin itching, ordinary personal care products cannot effectively solve this problem due to their single efficacy; some skin care products add effective active ingredients, but because their ingredients are unstable or have poor compatibility, they are not easy to be added to the existing daily chemical formulas. Summary of the invention

[0009] In view of the above problems, the purpose of the present invention is to provide a composition for relieving chronic skin itching, a preparation method and an application. The composition contains multifunctional effective active ingredients such as moisturizing, repairing and anti-inflammatory. The effective ingredients are coated with alcohol-soluble proteins to form a stable emulsion. The composition is suitable for the formulation of various washing and skin care products and can effectively relieve chronic skin itching.

[0010] To achieve the above object, the technical solution of the present invention is as follows:

[0011] A composition for relieving chronic skin itching, comprising an aqueous phase, a non-aqueous phase and an emulsifier. The aqueous phase comprises a water-soluble food-drug homologue and an active substance A phase, the non-aqueous phase comprises a non-water-soluble food-drug homologue and an active substance B phase, and the emulsifier comprises an alcohol-soluble protein.

[0012] Furthermore, the mass ratio of the aqueous phase to the non-aqueous phase is (30-95):(70-5), and the total mass concentration of the emulsifier in the non-aqueous phase is 0.1-3%.

[0013] Furthermore, the aqueous phase contains 1-40 parts of water-soluble food and medicine homologues and 1.5-32 parts of active substance phase A based on the total mass of the solution as 100 parts; the non-aqueous phase contains 0.1-20 parts of water-insoluble food and medicine homologues and 0.2-35 parts of active substance phase B based on the total mass of the solution as 100 parts.

[0014] Furthermore, the water-soluble medicinal and edible substances are one or a combination of two or more of the extraction products or fermentation products of Pleurotus ferulae, Ganoderma lucidum, Tremella fuciformis, Salvia miltiorrhiza, White ginseng, Tiger milk mushroom, Pleurotus citrinopileatus, Gentiana scabra, Stephania tetrandra, Camellia sinensis, algae, Portulaca oleracea, Calendula officinalis, Ophiopogon japonicus, Sophora flavescens, Centella asiatica, Blue water lily, tea, Agaricus rutaecarpa, Lentinus edodes, Agaricus bisporus, and Agaricus bisporus.

[0015] Furthermore, the water-soluble edible and medicinal substance is one or a combination of two or more selected from Tremella fuciformis polysaccharide, Pleurotus ostreatus polysaccharide, Agaricus rutaecarpa extract, Agaricus bisporus extract, and one or a combination of two or more selected from Gentiana root extract, Stephania tetrandra extract, Centella asiatica extract, and Camellia chinensis leaf extract.

[0016] Furthermore, the active substance phase A includes one or a combination of two or more of panthenol, dipotassium glycyrrhizinate, 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid, and allantoin.

[0017] Furthermore, the active substance phase A includes one or a combination of two or more of panthenol and allantoin, and one or a combination of two or more of dipotassium glycyrrhizinate and 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid.

[0018] Furthermore, the non-water-soluble medicinal and edible substances include one or a combination of two or more of the extraction products or fermentation products of Poria cocos, Kava Piper, Olive, Artemisia annua, Oats, Prinus prilocaensis, and Patchouli.

[0019] Furthermore, the non-water-soluble food-drug homologues include Poria cocos sclerotium extract, and one or a combination of two or more of Kava Piper melongena root extract, olive leaf extract, oat kernel oil, Prinus utilis oil, and Patchouli leaf oil.

[0020] Furthermore, the active substance phase B includes one or a combination of two or more of lecithin, ceramide, hydroxyphenylpropionamide benzoic acid, bisabolol, and trans-4-tert-butyl cyclohexanol.

[0021] Furthermore, the active phase B includes hydrogenated lecithin, ceramide, and one of hydroxyphenylpropionamide benzoic acid, bisabolol, and trans-4-tert-butylcyclohexanol.

[0022] Furthermore, the alcohol-soluble protein includes one or a combination of two or more of zein, gliadin, kaoliang, glutinous rice, millet and coix seed; preferably zein and gliadin.

[0023] Most preferably, based on 100 parts by total mass of the aqueous phase solution, the water-soluble food-medicine homologue comprises 1.5-25 parts of one or more combinations of Agaricus rutaecarpa polysaccharide and Agaricus rutaecarpa extract, and 5-15 parts of one or more combinations of one or more combinations of Gentiana root extract, Stephania tetrandra extract, and Centella asiatica extract; the active substance phase A comprises 1.5-25 parts of panthenol and 1.5-6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid; based on 100 parts by total mass of the non-aqueous phase solution, the non-water-soluble food-medicine homologue comprises 0.1-5 parts of Poria cocos sclerotium extract and 0.5-15 parts of Kava Piper methysticum root extract; the active substance phase B comprises 0.1-8 parts of hydrogenated lecithin, 0.1-8 parts of ceramide, and 0.3-18 parts of trans-4-tert-butyl cyclohexanol; the alcohol-soluble protein is 0.1-3 parts of zein.

[0024] A method for preparing a composition for relieving chronic skin itching comprises the following steps:

[0025] (1) dissolving or dispersing the water-soluble edible and medicinal substances and active substance A in water;

[0026] (2) dissolving or dispersing the alcohol-soluble protein in a solvent, then adding the water-insoluble edible and medicinal congeners and the active substance B to the solution, stirring and dispersing the mixture evenly to obtain an alcohol-water solution;

[0027] (3) slowly pouring the alcohol aqueous solution of step (2) into the solution of step (1), stirring, and then subjecting to ultrasonic emulsification treatment to obtain a composition for relieving chronic skin itching;

[0028] The solvent in step (2) is an alcohol aqueous solution, wherein the alcohol is one or a combination of two or more of ethanol, isopropanol, propylene glycol, butylene glycol, 1,2-pentanediol, hexylene glycol, polyethylene glycol, and polypropylene glycol; the mass ratio of alcohol to water is (10-30):(70-90); the stirring temperature in step (3) is 30-50°C, and the stirring time is 0.25-2h; the ultrasonic power of ultrasonic emulsification is 400-800W, and the working time of ultrasonic emulsification is 10-60s.

[0029] The application of the above-mentioned composition for relieving chronic skin itching is applied to daily chemical products, including washing and skin care products, especially to shower gel, toner, body lotion, essence and face cream.

[0030] Beneficial effects of the present invention:

[0031] (1) The composition of the present invention comprises a medicinal and edible substance, an active ingredient and an emulsifier, and acts on the four skin barriers, namely, the microbial barrier, the chemical barrier, the lipid barrier and the immune barrier, through different mechanisms of action to repair the skin.

[0032] (2) Extracts or fermentation products of medicinal and edible properties (such as Agaricus rutaecarpa polysaccharide, Agaricus rutaecarpa extract, Gentiana root extract, Stephania tetrandra extract, Centella asiatica extract, etc.) and panthenol in active ingredient phase A can maintain the moisture content of the skin to ensure that the stratum corneum is at an appropriate hydration level, resist the penetration of chemical substances, accelerate the recovery of the epidermal permeability barrier, and maintain the chemical barrier.

[0033] (3) Extracts or fermentation products of medicinal and edible fungi (such as extracts of Poria cocos sclerotium) can promote the growth of beneficial bacteria, inhibit and reduce harmful bacteria, and help the skin repair its microbial barrier.

[0034] (4) The ceramide in the active ingredient phase B can be encapsulated by hydrogenated lecithin. Ceramide penetrates deep into the skin due to the excellent compatibility of hydrogenated lecithin with the human skin cell membrane, thereby replenishing intercellular lipids, maintaining the integrity of the morphological structure and function of the stratum corneum, accelerating the synthesis of epidermal lipids, and repairing and improving the skin's lipid barrier.

[0035] (5) 2-Methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid in active ingredient phase A and trans-4-tert-butyl cyclohexanol in active ingredient phase B can block the histamine, substance P, TRPV1, PGs, and LTs pathways to form a strong skin immune barrier.

[0036] (6) The present invention uses alcohol-soluble protein as an emulsifier, which is derived from plants and is naturally mild and can reduce itching caused by skin irritation; corn alcohol-soluble protein has excellent compatibility and can encapsulate a high content of effective ingredients in the non-aqueous phase and form a stable emulsion, which greatly improves the long-term stability of the raw materials of the composition and has high practical application value.

[0037] (7) The synergistic coupling of specific medicinal and edible congeners can produce a synergistic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 This is a graph showing the results of the skin barrier damage and repair test. Specific implementation methods

[0040] The technical scheme of the present invention is further described below in conjunction with the embodiments, but it should not be limited to this. The equivalent replacement of the technical scheme of the present invention should also be within the scope of protection. Unless otherwise specified, the devices and equipment used in the following examples are all conventional devices and equipment in the art. Unless otherwise specified, the raw materials used in the following examples can be obtained commercially. Unless otherwise specified, the technical means used in the following examples are all well-known technical means in the art.

[0041] Example 1

[0042] (1) Dissolve 1.5 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 12 parts of Centella asiatica extract, 1.5 parts of panthenol, and 1.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0043] (2) dissolving 0.15 parts of zein in an alcohol aqueous solution (ethanol:butanediol:water=10:10:80), then adding 0.15 parts of Poria cocos sclerotium extract, 0.75 parts of Kava root extract, 0.15 parts of hydrogenated lecithin, 0.15 parts of ceramide, and 0.375 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for zein, the total weight of the remaining items is 100 parts);

[0044] (3) Weigh 70% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 30% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 1 for relieving chronic skin itching.

[0045] Example 2

[0046] (1) dissolving 15 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 10 parts of Centella asiatica extract, 15 parts of panthenol, and 4 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0047] (2) dissolving 2 parts of zein in an alcohol aqueous solution (ethanol: butylene glycol: water = 10:10:80), then adding 2 parts of Poria cocos sclerotium extract, 10 parts of Kava Piper methysticum root extract, 2 parts of hydrogenated lecithin, 2 parts of ceramide, and 5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for zein, the total weight of the remaining items is 100 parts);

[0048] (3) Weigh 5% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 95% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 2 for relieving chronic skin itching.

[0049] Example 3

[0050] (1) dissolving 25 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 15 parts of Centella asiatica extract, 25 parts of panthenol, and 6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0051] (2) dissolving 2.5 parts of zein in an alcohol aqueous solution (ethanol:butanediol:water=10:10:80), and then adding 5 parts of Poria cocos sclerotium extract, 12.5 parts of Kava root extract, 7.5 parts of hydrogenated lecithin, 7.5 parts of ceramide, and 17.5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for zein, the total weight of the remaining items is 100 parts);

[0052] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 3 for relieving chronic skin itching.

[0053] Example 4 [Compared with Example 3, the water-soluble medicine and food have a wide range of homology]

[0054] (1) dissolving 15 parts of Pleurotus ferulae polysaccharide (prepared according to patent CN201510167505.1), 10 parts of Tremella fuciformis polysaccharide, 5 parts of Centella asiatica extract, 10 parts of Camellia oleifera extract, 25 parts of panthenol, and 6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0055] (2) dissolving 2.5 parts of zein in an alcohol aqueous solution (ethanol:butanediol:water=10:10:80), and then adding 5 parts of Poria cocos sclerotium extract, 12.5 parts of Kava root extract, 7.5 parts of hydrogenated lecithin, 7.5 parts of ceramide, and 17.5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for zein, the total weight of the remaining items is 100 parts);

[0056] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 4 for relieving chronic skin itching.

[0057] Example 5 [Compared with Example 3, the range of active substance A is large]

[0058] (1) Dissolve 25 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 15 parts of Centella asiatica extract, 15 parts of panthenol, 10 parts of allantoin, 2.5 parts of 2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid, and 4 parts of dipotassium glycyrrhizinate in water to obtain a total of 100 parts of aqueous phase components;

[0059] (2) dissolving 2.5 parts of zein in an alcohol aqueous solution (ethanol:butanediol:water=10:10:80), and then adding 5 parts of Poria cocos sclerotium extract, 12.5 parts of Kava root extract, 7.5 parts of hydrogenated lecithin, 7.5 parts of ceramide, and 17.5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for zein, the total weight of the remaining items is 100 parts);

[0060] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 5 for relieving chronic skin itching.

[0061] Example 6 [Compared with Example 3, the scope of non-water-soluble medicine and food homology is large]

[0062] (1) dissolving 25 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 15 parts of Centella asiatica extract, 25 parts of panthenol, and 6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0063] (2) dissolving 2.5 parts of zein in an alcohol aqueous solution (ethanol:butylene glycol:water=10:10:80), and then adding 5 parts of kava root extract, 4.5 parts of olive leaf extract, 4 parts of oat kernel oil, 4 parts of patchouli leaf oil, 7.5 parts of hydrogenated lecithin, 7.5 parts of ceramide, and 17.5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for the zein, the total weight of the remaining items is 100 parts);

[0064] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 6 for relieving chronic skin itching.

[0065] Example 7 [Compared with Example 3, the range of active substance B is large]

[0066] (1) dissolving 25 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 15 parts of Centella asiatica extract, 25 parts of panthenol, and 6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0067] (2) dissolving 2.5 parts of zein in an alcohol aqueous solution (ethanol: butylene glycol: water = 10:10:80), and then adding 5 parts of Poria cocos sclerotium extract, 12.5 parts of Kava root extract, 7 parts of hydrogenated lecithin, 10 parts of bisabolol, 10 parts of trans-4-tert-butyl cyclohexanol, and 5.5 parts of hydroxyphenylpropionamide benzoic acid to the above solution, stirring and dispersing uniformly (except for zein, the total weight of the remaining items is 100 parts);

[0068] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 7 for relieving chronic skin itching.

[0069] Example 8 [Compared with Example 3, the non-aqueous phase range is large]

[0070] (1) dissolving 25 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 15 parts of Centella asiatica extract, 25 parts of panthenol, and 6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0071] (2) dissolving 2.5 parts of zein in an alcohol aqueous solution (ethanol: butylene glycol: water = 10:10:80), and then adding 5 parts of kava root extract, 4.5 parts of olive leaf extract, 4 parts of oat kernel oil, 4 parts of patchouli leaf oil, 7 parts of hydrogenated lecithin, 10 parts of bisabolol, 10 parts of trans-4-tert-butyl cyclohexanol, and 5.5 parts of hydroxyphenylpropionamide benzoic acid to the above solution, stirring and dispersing uniformly (except for the zein, the total weight of the remaining items is 100 parts);

[0072] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 40° C. for 0.5 h, and perform ultrasonic emulsification treatment at 800 W for 30 s to obtain a composition 8 for relieving chronic skin itching.

[0073] Example 9

[0074] (1) dissolving 15 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 7.5 parts of Agaricus rutaecarpa extract, 15 parts of Stephania tetrandra extract, 15 parts of panthenol, and 4 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0075] (2) dissolving 2.5 parts of gliadin in an alcohol-water solution (ethanol: water = 30:70), and then adding 5 parts of Poria cocos sclerotium extract, 12.5 parts of Kava root extract, 7.5 parts of hydrogenated lecithin, 7.5 parts of ceramide, and 17.5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for gliadin, the total weight of the remaining items is 100 parts);

[0076] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 30° C. for 1 h, and perform ultrasonic emulsification treatment at 800 W for 60 s to obtain a composition 9 for relieving chronic skin itching.

[0077] Example 10

[0078] (1) dissolving 7.5 parts of Pleurotus eryngii polysaccharide (prepared according to patent CN201810172232.3), 15 parts of Agaricus rutaecarpa extract, 15 parts of Gentiana root extract, 22.5 parts of panthenol, and 6 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid in water to obtain a total of 100 parts of aqueous phase components;

[0079] (2) dissolving 2.5 parts of gliadin in an alcohol aqueous solution (ethanol:butanediol:water=5:5:90), then adding 5 parts of Poria cocos sclerotium extract, 12.5 parts of Kava root extract, 7.5 parts of hydrogenated lecithin, 7.5 parts of ceramide, and 17.5 parts of trans-4-tert-butyl cyclohexanol to the above solution, stirring and dispersing uniformly (except for gliadin, the total weight of the remaining items is 100 parts);

[0080] (3) Weigh 40% by weight of the alcohol aqueous solution of step (2) and slowly pour it into 60% by weight of the solution of step (1), stir at 50° C. for 0.25 h, and perform ultrasonic emulsification treatment at 400 W for 10 s to obtain a composition 10 for relieving chronic skin itching.

[0081] Comparative Example 1 (Compared with Example 3, Comparative Example 1 does not add prolamin)

[0082] Compared with Example 3, other conditions are the same, except that the alcohol-soluble protein in Example 3 is replaced by water.

[0083] Comparative Example 2 (Compared with Example 3, in Comparative Example 2, prolamin was replaced with a conventional emulsifier)

[0084] Compared with Example 3, other conditions are the same, except that the alcohol-soluble protein in Example 3 is replaced by a conventional emulsifier: polysorbate-20 (a non-ionic emulsifier is selected to eliminate the influence of ions on the product).

[0085] Comparative Example 3 (Compared with Example 3, Comparative Example 3 does not add active ingredient B)

[0086] Compared with Example 3, other conditions are the same, except that the active substance B in Example 3 is replaced by water.

[0087] Comparative Example 4 (Compared with Example 3, Comparative Example 4 does not add non-water-soluble medicine and food)

[0088] Compared with Example 3, other conditions are the same, except that the non-water-soluble food and medicine in Example 3 is replaced by water.

[0089] Comparative Example 5 (Compared with Example 3, Comparative Example 5 does not add active ingredient A)

[0090] Compared with Example 3, other conditions are the same, except that the active substance A in Example 3 is replaced by water.

[0091] Comparative Example 6 (Compared with Example 3, Comparative Example 6 does not add water-soluble medicine and food)

[0092] Compared with Example 3, other conditions are the same, except that the water-soluble medicine and food in Example 3 are replaced by water.

[0093] Examples 1-10 and Comparative Examples 1-6 were left to stand at room temperature for 1 day, 7 days, and 30 days to observe their stability. No oil-water separation was marked as ○, slight oil-water separation was marked as △, and complete oil-water separation was marked as ×. The relevant results are recorded in Table 1.

[0094] Table 1

[0095] Sample name 1d 7d 30d Example 1 ○ ○ ○ Example 2 ○ ○ ○ Example 3 ○ ○ ○ Example 4 ○ ○ ○ Example 5 ○ ○ ○ Example 6 ○ ○ ○ Example 7 ○ ○ ○ Example 8 ○ ○ ○ Example 9 ○ ○ ○ Example 10 ○ ○ ○ Comparative Example 1 △ × × Comparative Example 2 ○ △ × Comparative Example 3 ○ ○ ○ Comparative Example 4 ○ ○ ○ Comparative Example 5 ○ ○ △ Comparative Example 6 ○ ○ △

[0096] As can be seen from the experimental results, in Examples 1-10, regardless of the level of non-aqueous phase content, the stability of the emulsion can be maintained for a long time in the presence of the emulsifier alcohol-soluble protein, alcohol-soluble protein can coat the effective ingredients of the high-content non-aqueous phase and form a stable emulsion, which greatly improves the long-term stability of the composition raw material, and has a high practical application value; Comparative Example 3 and Comparative Examples 1-2 and Comparative Examples 3-6 can be seen that the comparative example 1 without alcohol-soluble protein as an emulsifier has slight oil-water separation on the first day, and is completely separated after 7 days, which is extremely unstable; and the comparative example 2 adding a conventional emulsifier can only keep the emulsion stable at the beginning, and cannot be preserved for a long time. This shortcoming causes the composition to be unable to be stably used in daily chemical products. As can be seen from the experimental results of Comparative Examples 3-4, when the oil phase component is less, a certain amount of alcohol-soluble protein is added, which can also help stabilize the emulsion formed; but as can be seen from the experimental results of Comparative Examples 5-6, when some effective water-soluble components are reduced (i.e., the effective non-water-soluble component ratio increases), the long-term stable emulsion effect formed by alcohol-soluble protein is weakened.

[0097] In vitro soothing effect: Inflammatory factor inhibition test based on RAW264.7 macrophages

[0098] RAW264.7 macrophages were cultured at 2.2×10 5 / well inoculated into a 96-well plate, 2 mL of cell suspension was added to each well, and the inoculated cell culture plate was placed in an incubator for further culture for 24 h (5% CO2, 37°C). The old cell culture medium in the well was discarded. 1.8 mL of culture medium containing the corresponding mass concentrations of the composition 1-10 (7d) for relieving chronic itching of the skin and the comparative composition 3-6 (7d) was added to each well of the experimental sample group. The sample mass concentration was selected based on the results of the sample cytotoxicity test on RAW264.7 macrophages;

[0099] Comparative Example 7 was a negative control group, and 1.8 mL of solvent control culture medium was added to each well;

[0100] Comparative Example 8 was a blank control group, and 1.8 mL of normal culture medium was added to each well;

[0101] After the administration, the 6-well plate was placed in a cell culture incubator for 2 hours. After 2 hours, 200 μL of the prepared LPS solution was added to each well of each group and the cells were placed in a cell culture incubator for further 22 hours. The cell culture supernatant was collected and tested according to the instructions of the ELISA kit. The inhibition rate results are listed in Table 2 with the data of Comparative Example 7 as a comparison.

[0102] Table 2

[0103]

[0104]

[0105] Compared with the blank group of Comparative Example 8, the IL-1α, TNF-α, and PGE 2 contents of the negative control group of Comparative Example 7 increased significantly, indicating that the stimulation conditions of this test are effective. Comparing the data of Examples 1-5 with Comparative Example 7, it can be seen that the composition for relieving chronic skin itching of the present application has a significant inhibitory effect on IL-1α, TNF-α, and PGE 2; comparing Examples 3, 9-10 with Examples 4-8, it can be seen that the synergistic coupling of specific medicinal and edible homologues can produce a synergistic effect. Comparing Example 3 with Comparative Examples 3-6, it is shown that the components of the in vitro soothing effect protected by the present application are indispensable, and the composition has a more excellent in vitro soothing effect.

[0106] In vitro moisturizing efficacy: Zebrafish moisturizing efficacy test

[0107] Normally developed 2dpf zebrafish were randomly selected and placed in a 6-well plate, with 15 placed in each well. The sample content of the composition 1-10 (7d) for relieving chronic skin itching and the comparative composition 3-6 (7d) was set to 0.9%. At the same time, comparative example 9 (blank control group) and comparative example 10 (water shortage model control group, 0.9% sodium chloride solution) were set, and the capacity of each well was 3mL of solution. After incubation in the dark at 28°C for 22 hours, 10 zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. The data were analyzed and collected using advanced image processing software, and the tail area (S) of the zebrafish was analyzed. The statistical analysis results of the tail area were used to evaluate the moisturizing effect of the composition for relieving chronic skin itching on zebrafish. The statistical processing results are expressed as Mean±SE, and the results are listed in

[0108] Table 3. The formula for calculating moisturizing effect is as follows:

[0109]

[0110] Table 3

[0111]

[0112]

[0113] Compared with the blank control group of comparative example 9, the tail area of ​​zebrafish in the model control group of comparative example 10 was reduced, indicating that the zebrafish moisturizing and moisturizing efficacy evaluation model was successful. The tail area of ​​zebrafish in the sample group with a content of 0.9% of the composition 1-10 for relieving chronic skin itching was significantly increased compared with the model group of comparative example 10, and both had good moisturizing effects; by comparing Example 3 with Examples 4-8, it can be seen that the synergistic coupling of specific medicinal and edible homologues can enhance the moisturizing effect. By comparing Example 3 with Comparative Examples 3-6, it can be explained that the composition for relieving chronic skin itching composed of the proportions of the components of the present application can prevent water loss caused by high osmotic pressure and has a significant moisturizing effect.

[0114] Embodiment 11

[0115] Preparation of body lotion: Composition 3 for relieving chronic skin itching of Example 3 was used according to the formula of the body lotion in Table 4 below to prepare Example 11.

[0116] Comparative Example 11

[0117] Preparation of body lotion: Comparative Example 11 was prepared according to the formula of the body lotion in Table 4 below.

[0118] Heat phase A to 85°C and melt it, then add phase B which has been dispersed in water; heat phase C to 80°C, mix and homogenize phase C with phases A and B while stirring continuously, cool to below 40°C, then add phase D and stir to disperse evenly.

[0119] Table 4

[0120]

[0121]

[0122] Skin barrier damage and repair test: tape tear testSkin barrier damage and repair test: tape tear test

[0123] Male nude mice aged 8-10 weeks were selected and divided into a sample group (Example 11) and a control group (Comparative Example 11). First, 3cm*3cm test sites on the left and right sides of the nude mice were continuously pasted with tape and quickly torn off several times until small blood spots appeared on the skin. After stopping the pasting and tearing, each sample was applied once a day. After four consecutive days of application, the animals were killed and the skin tissue of the test sites was dissected and pathological sections were taken for microscopic examination and photography. The results are as follows Figure 1 shown.

[0124] from Figure 1It can be seen that the stratum corneum of the mice coated with the control group sample and the sample of Example 11 was basically not restored, and the stratum corneum was thin and discontinuous, while the stratum corneum of the epidermis of the mice coated with Example 11 containing the composition of the present application was well restored and restored to a certain thickness, and a good skin barrier was established, indicating that the composition for relieving chronic skin itching protected by the present application can be used in daily chemical products to play a good role in repairing the skin barrier.

[0125] Anti-allergic and antipruritic effects: Dextran antipruritic test in mice

[0126] Kunming mice with a body weight of (20±2) g were selected, half of which were male and half were female. After drug administration for 5 consecutive days, dextran saline injection was injected into the tail vein, and the number of itching times of each group of mice within 30 minutes was observed and recorded.

[0127] Comparative Example 12 used compound dexamethasone acetate cream as a positive control, and the test group used the body lotion of Example 11.

[0128] Comparative Example 13 is a blank control model group.

[0129] Table 5

[0130] Sample name Number of scratching in 30 minutes (times) Inhibition rate (%) Embodiment 11 15±3 60.53 Comparative Example 12 17±2 55.56 Comparative Example 13 38±3 /

[0131] Histamine is a medium released by mast cells during allergic reactions, which can promote the synthesis and secretion of pro-inflammatory cytokines and chemokines such as IL-1A, IL-18, 1L6, and 1L-8 in various cells and tissues, causing itching, dilation of capillaries and increased permeability, smooth muscle spasms, enhanced secretory activity, etc. Clinically, it can manifest as urticaria-like manifestations such as redness, swelling, itching, and blisters. The above experimental results show that the body lotion added with the composition for relieving chronic skin itching of the present application can effectively relieve itching, and has better anti-allergic and antipruritic effects than the commonly used compound dexamethasone acetate cream on the market.

[0132] Those skilled in the art should understand that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A composition for relieving chronic skin itching, characterized in that: The composition for relieving chronic skin itching comprises an aqueous phase, a non-aqueous phase and an emulsifier; the aqueous phase comprises a water-soluble food-drug homologue and an active substance A phase, the non-aqueous phase comprises a water-insoluble food-drug homologue and an active substance B phase, and the emulsifier comprises an alcohol-soluble protein.

2. A composition for relieving chronic skin itching according to claim 1, characterized in that: The mass ratio of the aqueous phase to the non-aqueous phase is (30-95):(70-5), and the mass concentration of the emulsifier in the non-aqueous phase is 0.1-3%.

3. A composition for relieving chronic skin itching according to claim 1, characterized in that: In the aqueous phase, based on the total mass of the solution being 100 parts, the water-soluble food-drug homologues are 1-40 parts, and the active substance phase A is 1.5-32 parts; in the non-aqueous phase, based on the total mass of the solution being 100 parts, the water-insoluble food-drug homologues are 0.1-20 parts, and the active substance phase B is 0.2-35 parts.

4. A composition for relieving chronic skin itching as claimed in claims 1-2, characterized in that: The water-soluble medicinal and edible substances are one or more of the extracts or fermentation products of Pleurotus ferulae, Ganoderma lucidum, Tremella fuciformis, Salvia miltiorrhiza, White ginseng, Tiger milk mushroom, Pleurotus citrinopileatus, Gentiana scabra, Stephania tetrandra, Australian tea with broom leaves, algae, Portulaca oleracea, Calendula officinalis, Ophiopogon japonicus, Sophora flavescens, Centella asiatica, Blue water lily, tea, Agaricus bisporus, Lentinus edodes, Agaricus bisporus, and the active substance A phase includes one or more of the following: panthenol, dipotassium glycyrrhizinate, 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid, and allantoin. The non-water-soluble medicinal and edible homologues include one or a combination of two or more of the extraction products or fermentation products of Poria cocos, Kava Piper, Olive, Artemisia annua, Oat, Prinia prioniae, and Patchouli; the active substance B phase includes one or a combination of two or more of lecithin, ceramide, hydroxyphenylpropionamide benzoic acid, bisabolol, and trans-4-tert-butyl cyclohexanol; the alcohol-soluble protein includes one or a combination of two or more of zein, gliadin, kaoliang, glutinous rice, millet, and coix seed.

5. A composition for relieving chronic skin itching according to claim 4, characterized in that: The water-soluble medicinal and edible substances are one or a combination of two or more selected from Tremella fuciformis polysaccharide, Pleurotus ostreatus polysaccharide, Agaricus rutinus extract, Agaricus bisporus extract, and one or a combination of two or more selected from Gentiana root extract, Stephania tetrandra extract, Centella asiatica extract, and Camellia oleracea extract; the active substance phase A includes one or a combination of two or more selected from panthenol and allantoin, and one or a combination of two or more selected from dipotassium glycyrrhizate and 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid.

6. A composition for relieving chronic skin itching according to claim 4, characterized in that: The non-water-soluble food-drug homologues include Poria cocos sclerotium extract, and one or more combinations of kava root extract, olive leaf extract, oat kernel oil, prune fruit oil, and patchouli leaf oil; the active substance phase B includes hydrogenated lecithin, and ceramide, and one or more combinations of hydroxyphenylpropionamide benzoic acid, bisabolol, and trans-4-tert-butyl cyclohexanol.

7. A composition for relieving chronic skin itching according to claim 5 or 6, characterized in that: Based on the total mass of the aqueous phase solution as 100 parts, the water-soluble food-medicine homologues include 1.5-25 parts of one or a combination of two or more selected from Agaricus rutaecarpa polysaccharides and Agaricus rutaecarpa extracts, and 5-15 parts of one or a combination of two or more selected from Gentiana root extract, Stephania tetrandra extract, and Centella asiatica extracts; the active substance phase A includes 1.5-25 parts of panthenol and 1.5-6.5 parts of 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid; based on the total mass of the non-aqueous phase solution as 100 parts, the non-water-soluble food-medicine homologues include 0.1-5 parts of Poria cocos sclerotium extract and 0.5-15 parts of Kava Piper methysticum root extract; the active substance phase B includes 0.1-8 parts of hydrogenated lecithin, 0.1-8 parts of ceramide, and 0.3-18 parts of trans-4-tert-butyl cyclohexanol; and the alcohol-soluble protein is 0.1-3 parts of zein.

8. A method for preparing a composition for relieving chronic skin itching according to any one of claims 1 to 7, characterized in that: The following steps are involved: (1) dissolving or dispersing the water-soluble edible and medicinal substances and active substance A in water; (2) dissolving or dispersing the alcohol-soluble protein in a solvent, then adding the water-insoluble edible and medicinal congeners and the active substance B to the solution, stirring and dispersing the mixture evenly to obtain an alcohol-water solution; (3) slowly pouring the alcohol aqueous solution of step (2) into the solution of step (1), stirring, and then subjecting to ultrasonic emulsification treatment to obtain a composition for relieving chronic skin itching.

9. The preparation method according to claim 8, characterized in that: The solvent in step (2) is an alcohol aqueous solution, wherein the alcohol is one or a combination of two or more of ethanol, isopropanol, propylene glycol, butylene glycol, 1,2-pentanediol, hexylene glycol, polyethylene glycol, and polypropylene glycol; the mass ratio of alcohol to water is (10-30):(70-90); the stirring temperature in step (3) is 30-50°C, and the stirring time is 0.25-2h; the ultrasonic power of ultrasonic emulsification is 400-800W, and the working time of ultrasonic emulsification is 10-60s.

10. Use of a composition for relieving chronic skin itching according to any one of claims 1 to 7 or a composition for relieving chronic skin itching obtained by the preparation method according to any one of claims 8 to 9, characterized in that: The composition for relieving chronic skin itching is applied to daily chemical products, including washing and skin care products.

Images